title: Capacity of the golgi apparatus for biogenesis from the endoplasmic reticulum.
abstract: It is unclear whether the mammalian Golgi apparatus can form de novo from the ER or whether it requires a preassembled Golgi matrix. As a test, we assayed Golgi reassembly after forced redistribution of Golgi matrix proteins into the ER. Two conditions were used. In one, ER redistribution was achieved using a combination of brefeldin A (BFA) to cause Golgi collapse and H89 to block ER export. Unlike brefeldin A alone, which leaves matrix proteins in relatively large remnant structures outside the ER, the addition of H89 to BFA-treated cells caused ER accumulation of all Golgi markers tested. In the other, clofibrate treatment induced ER redistribution of matrix and nonmatrix proteins. Significantly, Golgi reassembly after either treatment was robust, implying that the Golgi has the capacity to form de novo from the ER. Furthermore, matrix proteins reemerged from the ER with faster ER exit rates. This, together with the sensitivity of BFA remnants to ER export blockade, suggests that presence of matrix proteins in BFA remnants is due to cycling via the ER and preferential ER export rather than their stable assembly in a matrix outside the ER. In summary, the Golgi apparatus appears capable of efficient self-assembly.
authors.affiliation: Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA.
authors.forename: Sapna
authors.initials: S
authors.lastname: Puri
authors.forename: Adam D
authors.initials: AD
authors.lastname: Linstedt
mesh_terms: D000818:Animals; D020126:Brefeldin A / Q000494:pharmacology; D022181:COP-Coated Vesicles / Q000187:drug effects / Q000378:metabolism*; D002451:Cell Compartmentation / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D002994:Clofibrate / Q000494:pharmacology; D004721:Endoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006056:Golgi Apparatus / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008854:Microscopy, Electron; D008856:Microscopy, Fluorescence; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D013449:Sulfonamides
chemical_list: D004791:Enzyme Inhibitors; D000960:Hypolipidemic Agents; D007546:Isoquinolines; D011500:Protein Synthesis Inhibitors; D013449:Sulfonamides; D020126:Brefeldin A; D002994:Clofibrate; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide